|
|
ǰǾǰó ҽ |
ǰ
ȸ
|
Ǿǰ 濡 ̵Ρ() ǰȸ(~12/14) |
[ֿ]
• : Ǿǰ 濡 ٸ ̵ ()
• ֿ䳻 : , Ǿǰ ߿䵵 ߿//̷ з ,ٰڷ
• ǰȸ : ~ '17.12.14()
• ó : ǰ info@kobia.kr ۺ |
[1] Ǿǰ 濡 ̵ ()? Ȯ
[2] ǰ() Ȯ
|
|
ħ |
WHO Ʒü Ͻ
|
躸DZⱸ(WHO) ǰ Ͻ/ о߿ Ʒüͷ Ű Կ ־ ް , WHO ο Ϸ ȭ
ħ Ȯ
|
|
ǥ
ڷ |
ӻ åȸ ڷ |
, ӻǽñ 11 27 ڿ ӻ å ȸ ǥڷ̴. ش ȸ 10 Ǿǰ Ģ ȳ ԵǴ ӻ Ȱ õƴ. ֿ ӻ հ ӻüм ǹ ż ȣ å ġ ̴.
ǥڷ Ȯ
|
|
|
|
|
ӻ Ȳ |
û |
|
ǰ |
|
ܰ |
ѱ
() |
20171204 |
̼ Ҽ ȯڸ 1 ġμ Pembrolizumab (MK-3475) + Epacadostat (INCB024360) ȭп Pembrolizumab + ȭп + ϴ 3 ӻ |
3 |
īƮ 25mg, 100mg |
()ѱ
Ἶ |
20171201 |
Ǵ ٹ ִ ڿ Daratumumab 3 , ٱ ӻ |
3 |
Daratumumab
(JNJ-54767414) |
ѱ
() |
20171201 |
༺ ȯڸ Pembrolizumab (MK-3475) +/- Ÿ MK-7162 ϴ 1b - ӻ |
1b |
MK-7162
Pembrolizumab |
|
|
ؿǾǰ 㰡Ȳ |
̱ |
|
|
|
Drug name |
Active Ingredients |
Submission Classification |
Company |
Approval date |
IMPOYZ
NDA #209483 |
CLOBETASOL PROPIONATE |
Ǵ |
PROMIUS PHARMA LLC |
11/28/2017 |
CLENPIQ
NDA #209589 |
SODIUM PICOSULFATE;MAGNESIUM OXIDE;ANHYDROUS CITRIC ACID |
ſ뷮 |
FERRING PHARMS INC |
11/28/2017 |
SUBLOCADE
NDA #209819 |
BUPRENORPHINE |
ſ뷮 |
INDIVIOR INC |
11/30/2017 |
OGIVRI
BLA #761074 |
TRASTUZUMAB-DKST |
- |
MYLAN GMBH |
12/01/2017 |
|
|
|
|
|
|
Name |
Active Substance |
Therapeutic Area |
Date of Authorisation / Refusal |
Tremfya |
guselkumab |
Psoriasis |
10/11/2017 |
Tookad |
padeliporfin di-potassium |
Prostatic Neoplasms |
10/11/2017 |
Adlumiz |
anamorelin hydrochloride |
Anorexia
Cachexia
Carcinoma, Non-Small-Cell Lung |
16/11/2017 |
|
|
ؿܹ̿Ǿǰ ӻȲ |
̱ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
NCT03360890 |
Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors |
Thyroid Cancer
Salivary Gland Cancer |
Drug: Pembrolizumab
Drug: Docetaxel |
University of Chicago |
Phase 2 |
NCT03359356 |
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) |
Alopecia Areata |
Drug: Dupilumab
Drug: Placebos |
Icahn School of Medicine at
Mount Sinai |
Phase 2 |
NCT03359239 |
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer |
Urothelial/Bladder Cancer, Nos |
Drug: Atezolizumab
Biological: PGV001
Drug: Poly ICLC
Drug: Normal saline |
Matthew Galsky
Genentech, Inc.
Icahn School of Medicine at
Mount Sinai |
Phase 1 |
NCT03358719 |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
Acute Myeloid Leukemia
Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia |
Biological:
DEC-205/NY-ESO-1 Fusion Protein
CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Poly ICLC |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1 |
NCT03361228 |
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors |
Advanced or Metastatic Solid Tumors |
Drug: INCB001158
Drug: Epacadostat
Drug: Pembrolizumab |
Incyte
Corporation |
Phase 1
Phase 2 |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug:
Midazolam 2 mg.. |
Janssen Research & Development, LLC |
Phase 1 |
NCT03357952 |
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: Daratumumab
Drug: JNJ-63723283 |
Janssen Research & Development, LLC |
Phase 1 |
|
|
|
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
|
NCT03361228 |
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors |
Advanced or Metastatic Solid Tumors |
Drug: INCB001158
Drug: Epacadostat
Drug: Pembrolizumab |
Incyte Corporation |
Phase 1
Phase 2 |
|
NCT03360734 |
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors |
Solid Tumor, Adult |
Biological: Gatipotuzumab and Tomuzotuximab |
Glycotope GmbH |
Phase 1 |
|
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug: Midazolam 2 mg... |
Janssen Research & Development, LLC |
Phase 1 |
|
NCT03357952 |
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: Daratumumab
Drug: JNJ-63723283 |
Janssen Research & Development, LLC |
Phase 1 |
|
|
|
߱ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor/
Collaborators |
Phases |
NCT03360630 |
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC |
Lung Cancer
Neoplasms |
Biological: Anti-PD-1 plus DC-CIK
Biological: Anti-PD-1 alone |
Capital Medical University
Duke University
Geneplus-Beijing Co. Ltd. |
Phase 1
Phase 2 |
NCT03359018 |
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma |
Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity |
Drug: Apatinib
Drug: Camrelizumab |
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd. |
Phase 2 |
|
|
ҽ |
Z̿, ִ Ը ̿Ǿǰ 3 ذ |
|
- Ű , 18 Ը
-1, 2 ϸ Ը 36 ִ
Z̿ ̿Ǿǰ Ըδ ִ Ը شϴ 3 ذߴ. ̿Ǿǰ Ź(CMO) о߿ ־ 1 ϴ Ⱑ ȴ.... ( )
|
|
ȸ ҽ |
|
|
|
|
|
|
|
|
|
|
|
| | [Űź] Ŭ ּ. If you don't want this type of information or e-mail, please [click here]. |
|
|
|
|
|